Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):247-262. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0449

View: 1274 Download: 130 Crossref: 2

Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):235-246. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0485

View: 1658 Download: 176 Crossref: 3

Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study

Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue

Clin Mol Hepatol. 2024;30(2):225-234. Published online January 24, 2024

DOI: https://doi.org/10.3350/cmh.2023.0515

View: 1551 Download: 135 Crossref: 1

JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis

Li Xie, Hui Chen, Li Zhang, Yue Ma, Yuan Zhou, Yong-Yu Yang, Chang Liu, Yu-Li Wang, Ya-Jun Yan, Jia Ding, Xiao Teng, Qiang Yang, Xiu-Ping Liu, Jian Wu

Clin Mol Hepatol. 2024;30(2):206-224. Published online January 8, 2024

DOI: https://doi.org/10.3350/cmh.2023.0506

View: 1524 Download: 126 Crossref: 2

Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients

Jinlin Hou, Edward Gane, Rozalina Balabanska, Wenhong Zhang, Jiming Zhang, Tien Huey Lim, Qing Xie, Chau-Ting Yeh, Sheng-Shun Yang, Xieer Liang, Piyawat Komolmit, Apinya Leerapun, Zenghui Xue, Ethan Chen, Yuchen Zhang, Qiaoqiao Xie, Ting-Tsung Chang, Tsung-Hui Hu, Seng Gee Lim, Wan-Long Chuang, Barbara Leggett, Qingyan Bo, Xue Zhou, Miriam Triyatni, Wen Zhang, Man-Fung Yuen

Clin Mol Hepatol. 2024;30(2):191-205. Published online January 8, 2024

DOI: https://doi.org/10.3350/cmh.2023.0422

View: 1256 Download: 110 Crossref: 1

Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment

Miguel Sogbe, Idoia Bilbao, Francesco P. Marchese, Jon Zazpe, Annarosaria De Vito, Marta Pozuelo, Delia D’Avola, Mercedes Iñarrairaegui, Carmen Berasain, Maria Arechederra, Josepmaria Argemi, Bruno Sangro

Clin Mol Hepatol. 2024;30(2):177-190. Published online December 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0426

View: 5135 Download: 184 Crossref: 1

Editorial

The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective

Carlos Jose Pirola, Silvia Sookoian

Clin Mol Hepatol. 2024;30(2):174-176. Published online February 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0082

View: 938 Download: 37 Crossref: 1

Steatotic liver disease: Know your enemies

Lung-Yi Mak

Clin Mol Hepatol. 2024;30(2):171-173. Published online February 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0078

View: 821 Download: 42 Crossref: 1

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2024;30(2):168-170. Published online March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0140

View: 941 Download: 27 Crossref: 1

JCAD, a new potential therapeutic target in cholestatic liver disease

Byoung Kuk Jang

Clin Mol Hepatol. 2024;30(2):166-167. Published online March 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0128

View: 763 Download: 24

Linvencovir: Paving the way for functional cure in hepatitis B

Jiwon Yang, Jonggi Choi

Clin Mol Hepatol. 2024;30(2):164-165. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0149

View: 707 Download: 25

Exploring the prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma

Ji Eun Han, Hyo Jung Cho

Clin Mol Hepatol. 2024;30(2):160-163. Published online February 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0141

View: 874 Download: 28

Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis

Atsumasa Komori

Clin Mol Hepatol. 2024;30(2):157-159. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0131

View: 689 Download: 42

Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen

Chen-Te Huang, Tai-Chung Tseng

Clin Mol Hepatol. 2024;30(2):154-156. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0120

View: 634 Download: 27

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Clin Mol Hepatol. 2024;30(2):150-153. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0116

View: 1186 Download: 37

Toward hepatitis C virus elimination using artificial intelligence

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2024;30(2):147-149. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0135

View: 826 Download: 40 Crossref: 1

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Viewed By 5135	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4999	MAFLD: How is it different from NAFLD?
Viewed By 4896	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3630	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3571	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 67	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 51	MAFLD: How is it different from NAFLD?

Search